ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 487,09
0,45%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Taysha Gene Therapies Inc (TSHA)

  7. Taysha Gene Therapies Inc (TSHA) Actualités

TSHA

Taysha Gene Therapies (TSHA)

Taysha Gene Therapies Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:TSHA
DateHeureSourceTitreSymboleSociété
07/06/202414h00GlobeNewswire Inc.Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TSHATaysha Gene Therapies Inc
31/05/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSHATaysha Gene Therapies Inc
30/05/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSHATaysha Gene Therapies Inc
14/05/202422h12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TSHATaysha Gene Therapies Inc
14/05/202422h01GlobeNewswire Inc.Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:TSHATaysha Gene Therapies Inc
07/05/202422h05GlobeNewswire Inc.Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14NASDAQ:TSHATaysha Gene Therapies Inc
02/05/202414h00GlobeNewswire Inc.Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett SyndromeNASDAQ:TSHATaysha Gene Therapies Inc
20/03/202418h30AllPennyStocks.comAnother Biotech Steals The Show Following Major Clinical Data ReleaseNASDAQ:TSHATaysha Gene Therapies Inc
19/03/202421h01GlobeNewswire Inc.Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical UpdatesNASDAQ:TSHATaysha Gene Therapies Inc
19/03/202412h27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:TSHATaysha Gene Therapies Inc
14/03/202421h26GlobeNewswire Inc.Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19NASDAQ:TSHATaysha Gene Therapies Inc
29/02/202414h00GlobeNewswire Inc.Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett SyndromeNASDAQ:TSHATaysha Gene Therapies Inc
15/02/202422h01GlobeNewswire Inc.Taysha Gene Therapies Provides Update on Deprioritized Pipeline ProgramsNASDAQ:TSHATaysha Gene Therapies Inc
09/02/202422h24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TSHATaysha Gene Therapies Inc
22/01/202414h00GlobeNewswire Inc.Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual ConferenceNASDAQ:TSHATaysha Gene Therapies Inc
10/01/202414h00GlobeNewswire Inc.Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett SyndromeNASDAQ:TSHATaysha Gene Therapies Inc
20/12/202322h20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TSHATaysha Gene Therapies Inc
19/12/202313h30PR Newswire (US)Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene TherapiesNASDAQ:TSHATaysha Gene Therapies Inc
29/11/202314h00GlobeNewswire Inc.Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome PatientsNASDAQ:TSHATaysha Gene Therapies Inc
14/11/202322h08GlobeNewswire Inc.Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical UpdatesNASDAQ:TSHATaysha Gene Therapies Inc
07/11/202314h00GlobeNewswire Inc.Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14NASDAQ:TSHATaysha Gene Therapies Inc
03/11/202321h40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TSHATaysha Gene Therapies Inc
24/10/202314h00GlobeNewswire Inc.Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual CongressNASDAQ:TSHATaysha Gene Therapies Inc
10/10/202314h00GlobeNewswire Inc.Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual CongressNASDAQ:TSHATaysha Gene Therapies Inc
05/10/202313h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:TSHATaysha Gene Therapies Inc
26/09/202314h00GlobeNewswire Inc.Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett SyndromeNASDAQ:TSHATaysha Gene Therapies Inc
21/09/202322h01Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:TSHATaysha Gene Therapies Inc
19/09/202322h52Dow Jones NewsTaysha Gene Therapies to End Development of TSHA-120 After FDA FeedbackNASDAQ:TSHATaysha Gene Therapies Inc
19/09/202322h01GlobeNewswire Inc.Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)NASDAQ:TSHATaysha Gene Therapies Inc
11/09/202322h01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TSHATaysha Gene Therapies Inc
 Showing the most relevant articles for your search:NASDAQ:TSHA

Dernières Valeurs Consultées

EU
CAP
Capgemini
NYSE
MCD
McDonalds
NASDAQ
MSFT
Microsoft
EU
AI
Air Liquide
EU
BEL20
Bel 20
EU
AF
Air FranceKLM
EU
LR
Legrand
NYSE
MRK
Merck
COIN
ETHUSD
Ethereum
COIN
BTCUSD
Bitcoin
NASDAQ
GOOGL
Alphabet
EU
SGO
Cie de SaintGobain
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés